BioDruas


Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence

Ira Jacobs*, Reginald Ewesuedo, Sadig Lula, Charles Zacharchuk

*Corresponding author: Pfizer Essential Health, Pfizer Inc, 235 East 42nd Street, New York, NY, 10017-5755, USA.

Email: ira.jacobs@pfizer.com

Supplementary Fig. S4 Downs and Black score of full-text observational studies: two studies^{1,2}



References

1. Wisman LAB, et al. A phase I dose-escalation and bioequivalence study of a trastuzumab biosimilar in healthy male volunteers. Clin Drug Investig. 2014;34:887-94.

2. Yin D, et al. A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01). Br J Clin Pharmacol. 2014;78:1281-90.